Acrolein enhances epigenetic modifications, FasL expression and hepatocyte toxicity induced by anti-HIV drug Zidovudine

Toxicology in Vitro

Volumn 35, Issue , 2016, Pages 66-76

  Ghare, Smita S ^a,b   Donde, Hridgandh ^a,b   Chen, Wei Yang ^a,b   Barker, David F ^a,b   Gobejishvilli, Leila ^a,b   McClain, Craig J ^a,b   Barve, Shirish S ^a,b   Joshi Barve, Swati ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Acrolein; Epigenetic promoter modifications; FasL; Hepatocytes; Hydralazine; Zidovudine (AZT)

Indexed keywords

ACROLEIN; ANTIRETROVIRUS AGENT; FAS ANTIGEN; FAS LIGAND; HISTONE H3; HYDRALAZINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; RNA POLYMERASE II; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HISTONE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; LIVER CELL; LIVER TOXICITY; NONHUMAN; PROMOTER REGION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CELL CULTURE; CELL SURVIVAL; DNA FRAGMENTATION; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; HEP-G2 CELL LINE; METABOLISM;

ACROLEIN; ANIMALS; ANTI-HIV AGENTS; APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; DNA FRAGMENTATION; EPIGENESIS, GENETIC; FAS LIGAND PROTEIN; HEP G2 CELLS; HEPATOCYTES; HISTONES; HUMANS; HYDRALAZINE; RATS; RNA POLYMERASE II; ZIDOVUDINE;

EID: 84975230058     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2016.05.013     Document Type: Article

References (64)

1. Acosta B.S., Grimsley E.W. Zidovudine-associated type B lactic acidosis and hepatic steatosis in an HIV-infected patient. South. Med. J. 1999, 92:421-423.
2. Banerjee A., Abdelmegeed M.A., Jang S., Song B.J. Zidovudine (AZT) and hepatic lipid accumulation: implication of inflammation, oxidative and endoplasmic reticulum stress mediators. PLoS One 2013, 8.
3. Benard A., Bonnet F., Tessier J.F., Fossoux H., Dupon M., Mercie P., Ragnaud J.M., Viallard J.F., Dabis F., Chene G., Groupe d'Epidemiologie Clinique du, S.e.A. Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care STDs 2007, 21:458-468.
4. Bica I., McGovern B., Dhar R., Stone D., McGowan K., Scheib R., Snydman D.R. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 2001, 32:492-497.
5. Calingasan N.Y., Uchida K., Gibson G.E. Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J. Neurochem. 1999, 72:751-756.
6. Carmella S.G., Chen M., Zhang Y., Zhang S., Hatsukami D.K., Hecht S.S. Quantitation of acrolein-derived (3-hydroxypropyl)mercapturic acid in human urine by liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry: effects of cigarette smoking. Chem. Res. Toxicol. 2007, 20:986-990.
7. Castellano R., Vire B., Pion M., Quivy V., Olive D., Hirsch I., Van Lint C., Collette Y. Active transcription of the human FASL/CD95L/TNFSF6 promoter region in T lymphocytes involves chromatin remodeling: role of DNA methylation and protein acetylation suggest distinct mechanisms of transcriptional repression. J. Biol. Chem. 2006, 281:14719-14728.
8. Cerami C., Founds H., Nicholl I., Mitsuhashi T., Giordano D., Vanpatten S., Lee A., Al-Abed Y., Vlassara H., Bucala R., Cerami A. Tobacco smoke is a source of toxic reactive glycation products. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:13915-13920.
9. Chariot P., Drogou I., de Lacroix-Szmania I., Eliezer-Vanerot M.C., Chazaud B., Lombes A., Schaeffer A., Zafrani E.S. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J. Hepatol. 1999, 30:156-160.
10. Crump N.T., Hazzalin C.A., Bowers E.M., Alani R.M., Cole P.A., Mahadevan L.C. Dynamic acetylation of all lysine-4 trimethylated histone H3 is evolutionarily conserved and mediated by p300/CBP. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:7814-7819.
11. de la Asuncion J.G., del Olmo M.L., Sastre J., Pallardo F.V., Vina J. Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver. Hepatology 1999, 29:985-987.
12. Desai V.G., Lee T., Moland C.L., Branham W.S., Mittelstaedt R.A., Lewis S.M., Leakey J.E., Fuscoe J.C. Evaluation of hepatic mitochondria and hematological parameters in Zidovudine-treated B6C3F(1) mice. AIDS Res Treat 2012, 2012:317695.
13. Eiserich J.P., van der Vliet A., Handelman G.J., Halliwell B., Cross C.E. Dietary antioxidants and cigarette smoke-induced biomolecular damage: a complex interaction. Am. J. Clin. Nutr. 1995, 62:1490S-1500S.
14. Fang J.L., Beland F.A. Long-term exposure to zidovudine delays cell cycle progression, induces apoptosis, and decreases telomerase activity in human hepatocytes. Toxicol. Sci. 2009, 111:120-130.
15. Fang J.L., Han T., Wu Q., Beland F.A., Chang C.W., Guo L., Fuscoe J.C. Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch. Toxicol. 2014, 88:609-623.
16. Feldstein A.E., Canbay A., Angulo P., Taniai M., Burgart L.J., Lindor K.D., Gores G.J. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125:437-443.
17. Freiman J.P., Helfert K.E., Hamrell M.R., Stein D.S. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 1993, 7:379-385.
18. Galle P.R., Hofmann W.J., Walczak H., Schaller H., Otto G., Stremmel W., Krammer P.H., Runkel L. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 1995, 182:1223-1230.
19. Galvan F.H., Bing E.G., Fleishman J.A., London A.S., Caetano R., Burnam M.A., Longshore D., Morton S.C., Orlando M., Shapiro M. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV cost and services utilization study. J. Stud. Alcohol 2002, 63:179-186.
20. Ghare S., Patil M., Hote P., Suttles J., McClain C., Barve S., Joshi-Barve S. Ethanol inhibits lipid raft-mediated TCR signaling and IL-2 expression: potential mechanism of alcohol-induced immune suppression. Alcohol. Clin. Exp. Res. 2011, 35:1435-1444.
21. Ghare S.S., Joshi-Barve S., Moghe A., Patil M., Barker D.F., Gobejishvili L., Brock G.N., Cave M., McClain C.J., Barve S.S. Coordinated histone H3 methylation and acetylation regulate physiologic and pathologic fas ligand gene expression in human CD4+ T cells. J. Immunol. 2014, 193:412-421.
22. Gobejishvili L., Avila D.V., Barker D.F., Ghare S., Henderson D., Brock G.N., Kirpich I.A., Joshi-Barve S., Mokshagundam S.P., McClain C.J., Barve S. S-adenosylmethionine decreases lipopolysaccharide-induced phosphodiesterase 4B2 and attenuates tumor necrosis factor expression via cAMP/protein kinase A pathway. J. Pharmacol. Exp. Ther. 2011, 337:433-443.
23. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389:349-352.
24. Holtz-Heppelmann C.J., Algeciras A., Badley A.D., Paya C.V. Transcriptional regulation of the human FasL promoter-enhancer region. J. Biol. Chem. 1998, 273:4416-4423.
25. Hristova M., Spiess P.C., Kasahara D.I., Randall M.J., Deng B., van der Vliet A. The tobacco smoke component, acrolein, suppresses innate macrophage responses by direct alkylation of c-Jun N-terminal kinase. Am. J. Respir. Cell Mol. Biol. 2012, 46:23-33.
26. Johnson A.A., Ray A.S., Hanes J., Suo Z., Colacino J.M., Anderson K.S., Johnson K.A. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J. Biol. Chem. 2001, 276:40847-40857.
27. Kalyesubula R., Kagimu M., Opio K.C., Kiguba R., Semitala C.F., Schlech W.F., Katabira E.T. Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. Afr. Health Sci. 2011, 11:16-23.
28. Kanzler S., Galle P.R. Apoptosis and the liver. Semin. Cancer Biol. 2000, 10:173-184.
29. Kavurma M.M., Khachigian L.M. Signaling and transcriptional control of Fas ligand gene expression. Cell Death Differ. 2003, 10:36-44.
30. Kuhla A., Thrum M., Schaeper U., Fehring V., Schulze-Topphoff U., Abshagen K., Vollmar B. Liver-specific Fas silencing prevents galactosamine/lipopolysaccharide-induced liver injury. Apoptosis 2015, 20:500-511.
31. Liang G., Lin J.C., Wei V., Yoo C., Cheng J.C., Nguyen C.T., Weisenberger D.J., Egger G., Takai D., Gonzales F.A., Jones P.A. Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:7357-7362.
32. Liu-Snyder P., Borgens R.B., Shi R. Hydralazine rescues PC12 cells from acrolein-mediated death. J. Neurosci. Res. 2006, 84:219-227.
33. Li-Weber M., Krammer P.H. Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system. Semin. Immunol. 2003, 15:145-157.
34. Lloyd-Richardson E.E., Stanton C.A., Papandonatos G.D., Betancourt R.M., Stein M., Tashima K., Morrow K., Niaura R. HIV-positive smokers considering quitting: differences by race/ethnicity. Am. J. Health Behav. 2008, 32:3-15.
35. Lovell M.A., Markesbery W.R. Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid. Arch. Neurol. 2001, 58:392-396.
36. Malhi H., Guicciardi M.E., Gores G.J. Hepatocyte death: a clear and present danger. Physiol. Rev. 2010, 90:1165-1194.
37. McGowan J.P., Shah S.S. Prevention of perinatal HIV transmission during pregnancy. J. Antimicrob. Chemother. 2000, 46:657-668.
38. Miguez M.J., Shor-Posner G., Morales G., Rodriguez A., Burbano X. HIV treatment in drug abusers: impact of alcohol use. Addict. Biol. 2003, 8:33-37.
39. Moghe A., Ghare S., Lamoreau B., Mohammad M., Barve S., McClain C., Joshi-Barve S. Molecular mechanisms of acrolein toxicity: relevance to human disease. Toxicol. Sci. 2015, 143:242-255.
40. Mohammad M.K., Avila D., Zhang J., Barve S., Arteel G., McClain C., Joshi-Barve S. Acrolein cytotoxicity in hepatocytes involves endoplasmic reticulum stress, mitochondrial dysfunction and oxidative stress. Toxicol. Appl. Pharmacol. 2012, 265:73-82.
41. Muller M., Strand S., Hug H., Heinemann E.M., Walczak H., Hofmann W.J., Stremmel W., Krammer P.H., Galle P.R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 1997, 99:403-413.
42. Muscat J.E., Harris R.E., Haley N.J., Wynder E.L. Cigarette smoking and plasma cholesterol. Am. Heart J. 1991, 121:141-147.
43. Nunez M., Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf. 2005, 28:53-66.
44. Palella F.J., Baker R.K., Moorman A.C., Chmiel J.S., Wood K.C., Brooks J.T., Holmberg S.D., Investigators H.I.V.O.S. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J. Acquir. Immune Defic. Syndr. 2006, 43:27-34.
45. Papadopoulou M.V., Bloomer W.D. DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agents. In Vivo 2007, 21:175-180.
46. Pianko S., Patella S., Ostapowicz G., Desmond P., Sievert W. Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection. J. Viral Hepat. 2001, 8:406-413.
47. Price J.C., Thio C.L. Liver disease in the HIV-infected individual. Clin. Gastroenterol. Hepatol. 2010, 8:1002-1012.
48. Purevjav E., Nelson D.P., Varela J.J., Jimenez S., Kearney D.L., Sanchez X.V., DeFreitas G., Carabello B., Taylor M.D., Vatta M., Shearer W.T., Towbin J.A., Bowles N.E. Myocardial Fas ligand expression increases susceptibility to AZT-induced cardiomyopathy. Cardiovasc. Toxicol. 2007, 7:255-263.
49. Roh T.Y., Cuddapah S., Zhao K. Active chromatin domains are defined by acetylation islands revealed by genome-wide mapping. Genes Dev. 2005, 19:542-552.
50. Roh T.Y., Cuddapah S., Cui K., Zhao K. The genomic landscape of histone modifications in human T cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:15782-15787.
51. Sacktor N., Haughey N., Cutler R., Tamara A., Turchan J., Pardo C., Vargas D., Nath A. Novel markers of oxidative stress in actively progressive HIV dementia. J. Neuroimmunol. 2004, 157:176-184.
52. Sakata K., Kashiwagi K., Sharmin S., Ueda S., Irie Y., Murotani N., Igarashi K. Increase in putrescine, amine oxidase, and acrolein in plasma of renal failure patients. Biochem. Biophys. Res. Commun. 2003, 305:143-149.
53. Satoh K., Yamada S., Koike Y., Igarashi Y., Toyokuni S., Kumano T., Takahata T., Hayakari M., Tsuchida S., Uchida K. A1-hour enzyme-linked immunosorbent assay for quantitation of acrolein- and hydroxynonenal-modified proteins by epitope-bound casein matrix method. Anal. Biochem. 1999, 270:323-328.
54. Schattenberg J.M., Worns M.A., Zimmermann T., He Y.W., Galle P.R., Schuchmann M. The role of death effector domain-containing proteins in acute oxidative cell injury in hepatocytes. Free Radic. Biol. Med. 2012, 52:1911-1917.
55. Senise J.F., Castelo A., Martinez M. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy. AIDS Rev. 2011, 13:198-213.
56. Sturt A.S., Dokubo E.K., Sint T.T. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst. Rev. 2010.
57. Sun Y., Ito S., Nishio N., Tanaka Y., Chen N., Isobe K. Acrolein induced both pulmonary inflammation and the death of lung epithelial cells. Toxicol. Lett. 2014, 229:384-392.
58. Szabados E., Fischer G.M., Toth K., Csete B., Nemeti B., Trombitas K., Habon T., Endrei D., Sumegi B. Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat. Free Radic. Biol. Med. 1999, 26:309-317.
59. Teto G., Kanmogne G.D., Torimiro J.N., Alemnji G., Nguemaim F.N., Takou D., Nanfack A., Tazoacha A. Lipid peroxidation and total cholesterol in HAART-naive patients infected with circulating recombinant forms of human immunodeficiency virus type-1 in Cameroon. PLoS One 2013, 8.
60. Tsukahara H., Haruta T., Todoroki Y., Hiraoka M., Noiri E., Maeda M., Mayumi M. Oxidant and antioxidant activities in childhood meningitis. Life Sci. 2002, 71:2797-2806.
61. Vassimon H.S., Deminice R., Machado A.A., Monteiro J.P., Jordao A.A. The association of lipodystrophy and oxidative stress biomarkers in HIV-infected men. Curr. HIV Res. 2010, 8:364-369.
62. website, A. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States 2016.
63. Woreta T.A., Sutcliffe C.G., Mehta S.H., Brown T.T., Higgins Y., Thomas D.L., Torbenson M.S., Moore R.D., Sulkowski M.S. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology 2011, 140:809-817.
64. Zhang F., Chen L., Jin H., Shao J., Wu L., Lu Y., Zheng S. Activation of Fas death receptor pathway and Bid in hepatocytes is involved in saikosaponin D induction of hepatotoxicity. Environ. Toxicol. Pharmacol. 2015, 41:8-13.